培训课件-冠心病危险因素的防治.pptVIP

* Summary (I) In patients at high or moderately risk, therapeutic lifestyle change is an integral part of risk reduction. If an LDL-C–lowering drug is used, the intensity of therapy should achieve an additional LDL-C reduction of at least 30–40% beyond diet. * * * In the HPS, similar reductions in absolute risk of major vascular events with simvastatin extended over a range of baseline cholesterol levels. At a baseline LDL-C 100 mg/dl, the optimal target set by the National Cholesterol Education Program ATP III,8 major vascular events occurred in 358 patients on placebo (21.0% five-year abso